Syntara (ASX:SNT) Institutional Ownership : 0.57% (As of Sep. 26, 2024)

View and export this data going back to 2003. Start your Free Trial

What is Syntara Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Syntara's institutional ownership is 0.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Syntara's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Syntara's Float Percentage Of Total Shares Outstanding is 0.00%.

Syntara Institutional Ownership Historical Data

The historical data trend for Syntara's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Institutional Ownership Chart

Syntara Historical Data

The historical data trend for Syntara can be seen below:

	2020-02-29	2020-03-31	2020-04-30	2020-05-31	2020-06-30	2020-07-31	2020-08-31	2020-09-30	2020-10-31	2020-11-30
Institutional Ownership	2.10	1.44	1.44	1.44	0.89	0.76	0.69	0.57	0.57	0.57

Syntara Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Syntara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.syntaratx.com.au

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.